

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A23L 1/054, 1/00, C12P 19/06, A23L 2/00, A23G 3/00, A23L 1/39, 1/22, 1/24, A61K 9/107	A1	(11) International Publication Number: WO 99/25208 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/US98/23904 (22) International Filing Date: 10 November 1998 (10.11.98) (30) Priority Data: 08/971,067 14 November 1997 (14.11.97) US (71) Applicant (for all designated States except US): RHODIA INC. [US/US]; 259 Prospect Plains Road, Cranbury, NJ 08512-7500 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HOPPE, Craig, Alan [US/US]; 11 Hancock Court, Plainsboro, NJ 08536 (US). LAWRENCE, Jeanette [US/US]; 17 Major Drive, Sayreville, NJ 08872 (US). SHAHEED, Amr [EG/US]; 32 Sherwood Road, Manalapan, NJ 07726 (US). (74) Agent: SOLOMON, Andrew, M.; Rhodia Inc., 259 Prospect Plains Road, Cranbury, NJ 08512-7500 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: USE OF LIQUID CARBOHYDRATE FERMENTATION PRODUCT IN FOODS (57) Abstract A food or pharmaceutical composition including a liquid composition comprising the fermentation product of a biologically active substance, in a carbohydrate medium other than dairy whey wherein said fermentation product has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition is provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF LIQUID CARBOHYDRATE FERMENTATION PRODUCT IN FOODS

Background of the Invention

5 1. Field of the Invention

The present invention relates to carbohydrate fermentation products which may be used in food or pharmaceutical applications and required minimal processing steps. More specifically, the invention comprises the use of a xanthan gum broth in liquid food or pharmaceutical
10 compositions wherein the broth medium is a carbohydrate other than whey and wherein the broth is used directly without the need for filtration and purification processing steps.

2. Technology Description

15 Carbohydrate fermentation products, such as xanthan gum, are commonly used as additives, such as thickening agents for food and pharmaceutical ingredients. The fermentation of carbohydrates to produce biosynthetic water-soluble gums by the action of *Xanthomonas* bacteria is well known. The earliest work in this field was conducted by the U.S. Department of Agriculture and is described in U.S. Pat. No. 3,000,790. Particularly well known is the action of
20 *Xanthomonas campestris* NRRL B-1459 on a glucose substrate.

Xanthomonas hydrophilic colloid (i.e., xanthan gum) is produced by transferring *Xanthomonas campestris* bacteria to a suitable medium and conditioning it to growth through two steps before allowing it to grow in a final medium containing 3 percent glucose. After 96 hours at 30° C. with
25 suitable aeration and stirring, Xanthomonas hydrophilic colloid is produced in approximately 1 percent concentration. Modified fermentation processes are described in U.S. Pat. Nos. 3,391,060; 3,391,061; 3,427,226; 3,455,786; 3,565,763; and the like.

Xanthomonas hydrophilic colloid is a microbial heteropolysaccharide which contains mannose,

glucose, glucuronic acid, O-acetyl radicals and acetal-linked pyruvic acid in a molar ratio of 2:2:1:1:0.5.

5 While *Xanthomonas campestris* is the bacteria of choice for the purpose of producing the biosynthetic *Xanthomonas* hydrophilic colloid, other *Xanthomonas* species may be employed such as *X. begoniae*, *X. malvacearum*, *X. carotae*, *X. incanae*, *X. phaseoli*, *X. vesicatoria*, *X. papavericola*, *X. translucens*, *X. vasculorum*, and *X. hedrae*.

10 In practice when xanthan gum is typically used as a thickening agent in a food or pharmaceutical composition, the fermentation broth is typically subject to processing conditions such as drying, centrifuging and the like to yield a purified powder. For example, In a typical process for clarification of a *Xanthomonas* fermentation broth and/or recovery of the *Xanthomonas* hydrocolloid component, the broth is diluted with water to reduce its viscosity, and optionally the diluted broth is centrifuged or filtered to remove suspended insoluble solids. A salt such as
15 potassium chloride and a nonsolvent such as methanol or isopropanol are added to the broth to flocculate the gum in the potassium form, which gum is then recovered by centrifugation or other solid/liquid separation technique. Further dissolution, reprecipitating and washing steps are usually employed. To yield xanthan gum powder, additional "downstream" processing steps such as drying, milling, sieving and packaging for customer use. There are significant
20 costs involved in such steps and it would be desirable to omit these steps for economic reasons.

In addition, while the xanthan gum powder compositions typically are capable of thickening liquid food compositions, additional improvements in viscosity performance would be desired in homogenized foods such as salad dressings.

25

U.S. Patent No. 4,299,825 suggests a process for clarifying and concentrating *Xanthomonas* heteropolysaccharide fermentation broth, which process includes filtration and ultrafiltration steps. The resulting clarified and concentrated material is suggested for use in foodstuffs, drugs and cosmetics, as well as a thickening agent for oil recovery operations. Despite the

advances suggested in the patent, the filtration and ultrafiltration steps add significant processing costs to the manufacturer.

U.S. Patent Nos. 4,442,128 and 4,444,792 suggests the fermentation of an organism such as *Xanthomonas campestris* in a dairy whey environment to yield a whey product containing a thickening polymer that serves as a thickening agent. The reference fails to suggest that other carbohydrate sources can be used as the fermentation medium.

Despite the above teachings, there still exists a need in the art for a carbohydrate fermentation product which can be produced using a minimum amount of unit processing steps and used directly in food or pharmaceutical applications.

There exists yet another need in the art for a thickening agent which demonstrates superior thickening properties in homogenized liquid foods, such as salad dressings.

Brief Summary of the Invention

In accordance with the present invention a food or pharmaceutical composition containing a carbohydrate fermentation product which is produced using a minimum amount of unit processing steps and used directly in food or pharmaceutical applications is provided. More specifically, the invention comprises a food or pharmaceutical composition including a liquid composition comprising the fermentation product of a biologically active substance, preferably xanthan gum in a carbohydrate medium other than dairy whey wherein said fermentation product has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition.

In preferred embodiments of the present invention, the carbohydrate medium is either glucose or hydrolyzed starch.

Another embodiment of the present invention comprises a homogenized liquid food or pharmaceutical composition including a thickening agent comprising the fermentation product of *Xanthomonas* in a carbohydrate medium other than dairy whey wherein said fermentation product has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition.

In preferred embodiments, the homogenized liquid food or pharmaceutical composition comprises a salad dressing, sauce or condiment.

Still another embodiment of the present invention comprises a method for making a food or pharmaceutical composition comprising the steps of:

(a) fermenting a food-grade biopolymer in a carbohydrate medium other than dairy whey to yield a liquid fermentation product; and

(b) directly adding said liquid fermentation product to food or pharmaceutical ingredients to yield a food or pharmaceutical composition.

In preferred embodiments of the present invention, the carbohydrate medium can be treated with acid prior to or during fermentation.

An object of the present invention is to provide a food or pharmaceutical composition which includes a liquid composition comprising the fermentation product of *Xanthomonas* in a carbohydrate medium other than dairy whey wherein said fermentation product has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition.

Still another object of the present invention is to provide a homogenized food product having improved viscosity properties.

A further object of the present invention is to provide a cost efficient process for producing foods which include the fermentation product of biopolymers.

5 These, and other objects, will readily be apparent to those skilled in the art as reference is made to the drawings and detailed description of the preferred embodiment.

Brief Description of the Drawings

10 Figures 1 and 2 are viscosity graphs for the Compositions of Examples 4 and 5

Detailed Description of the Preferred Embodiment

15 In describing the preferred embodiment, certain terminology will be utilized for the sake of clarity. Such terminology is intended to encompass the recited embodiment, as well as all technical equivalents which operate in a similar manner for a similar purpose to achieve a similar result.

20 The present invention provides for an economical way to utilize biopolymer fermentation products in food or pharmaceutical applications. In practice, the production of food grade fermentation products, such as xanthan gum powder, are produced by a sequence of process steps. Such steps typically include, in sequence, the following: strain selection, fermentation in a carbohydrate medium, thermal treatment, precipitation, centrifugation, drying, milling, sieving and packaging. The inventors have surprisingly discovered that the post fermentation steps may be omitted and a useful product obtained for liquid foodstuffs and pharmaceuticals with great costs savings to the end use manufacturer.

25 The first step of the inventive process involves the selection of the biologically active substance which through fermentation yields a biopolymer. The polymer is generically defined to include any and all which, after fermentation in a carbohydrate medium may have applications as additives in liquid food or pharmaceutical compositions. In preferred embodiments, the biopolymer selected is

derived from the group of polymers formed from fermentation of the genus *Xanthomonas*. While *Xanthomonas campestris* is the biologically active substance of choice for the purpose of producing the biosynthetic *Xanthomonas* hydrophilic colloid, other *Xanthomonas* species may be employed such as *X. begoniae*, *X. malvacearum*, *X. carotae*, *X. incanae*, *X. phaseoli*, *X. vesicatoria*, *X. papavericola*, *X. translucens*, *X. vasculorum*, and *X. hedrae*.

Examples of other biologically active substances include, but are not limited to the following materials: those of the genus *Leuconostoc* such as *Leuconostoc mesenteroides*, and those of the genus *Lactobacillus*, *Alcaligenes* or *Streptococcus* to yield polyglucans such as dextran; those of the genus *Saccharomyces* to yield yeast β -glucan; those of the genus *Pullularia* to yield pullulans and those of the genus *Pseudomonas* to yield gellan gum.

In practice, the biologically active substance is fermented in a carbohydrate substrate other than dairy whey which may be either of the monosaccharide, disaccharide or oligosaccharide structure.

Examples of substrates include glucose, dextrose, sucrose, fructose, mannose, lactose, starches such as hydrolyzed starch, maltodextrins and the like. The use of a glucose or a starch substrate is particularly preferred. The fermentation medium typically also contains organic nitrogen sources, phosphate salts which function to sequester calcium, more specifically alkali metal and ammonium phosphates as exemplified by dipotassium hydrogen phosphate and trace elements.

An example of a typical fermentation using *Xanthomonas campestris* as the biologically active material is as follows, although as would be known by those skilled in the art, like procedures could be used to ferment the other above-mentioned bacteria.

As described in U.S. Pat. No. 3,516,983 and 4,135,979, *Xanthomonas* hydrophilic colloid can be biosynthesized by whole culture *Xanthomonas campestris* fermentation of a medium containing 2–5 percent of commercial glucose, an organic nitrogen source, dipotassium hydrogen phosphate, and appropriate trace elements.

The incubation time of the final medium is approximately 96 hours at 30° C. under aerobic

conditions. In preparing the colloid, it is convenient to use corn steep liquor or distillers' dry solubles as an organic nitrogen source. It is convenient to grow the culture in two intermediate stages prior to the final inoculation in order to encourage vigorous growth of the bacteria. These stages may be carried out in media having a pH of about 7.

5

In the first stage a transfer from an agar slant to a dilute glucose broth may be made and the bacteria cultured for 24 hours under vigorous agitation and aeration at a temperature of about 30° C. The culture so produced may then be used to inoculate a higher glucose (3%) content broth of larger volume in a second intermediate stage. In this stage the reaction may be permitted to continue for 24 hours under the same conditions as the first stage. The culture so acclimated for use with glucose by the first and second stages is then added to the final glucose medium. In the said method of preparing *Xanthomonas campestris* hydrophilic colloid, a loopful of organism from the agar slant is adequate for the first stage comprising 290 milliliters of the glucose medium. In the second stage, the material resulting from the first stage may be used together with 9 times its volume of 3 percent glucose medium.

10
15

In the final stage the material produced in the second stage may be admixed with 19 times its volume of the final medium. A good final medium may contain 3 percent glucose, 0.5 percent distillers' solubles, 0.5 percent dipotassium phosphate, 0.1 percent magnesium sulfate having 7 molecules of water of crystallization, and water. The reaction in the final stage may be satisfactorily carried out for 96 hours at 30° C. with vigorous agitation and aeration.

20

The resultant raw *Xanthomonas* hydrophilic colloid fermentation liquor is referred to as a fermentation beer or a fermentation broth. A typical raw fermentation broth contains between about 0.5 to about 8.0, more preferably between about 3.0 to about 5.0 weight percent of dissolved *Xanthomonas* hydrophilic colloid, and has a viscosity in the range between about 500–100,000 cps at room temperature.

25

The broth is then subject to heat treatment for a time period and at a temperature suitable to deactivate the *Xanthomonas* organism. In prior art systems where the xanthan gum is ultimately recovered as a powder, both heat and isopropyl alcohol are used. In the present invention, no isopropyl alcohol is added.

5

The fermentation process of the present invention may also involve the addition of preservative agents after fermentation. The use of such preservatives is preferred as they function to extend the shelf-life of the resulting broth, which is directly added into foodstuffs and/or pharmaceuticals. Any food grade preservative may be selected but included amongst preferred materials are sodium benzoate and acidic materials such as acetic acid, which is most preferred. The amount of preservative added can range from about 0.1 to about 20% by weight of the broth, with amounts ranging from about 0.5% to about 10% being more preferred.

10

The fermentation product broth will typically contain between about 0.5% to about 10.0% of the preservative material.

15

The broth can contain other optional additive materials depending on the final desired use. For example, bactericides, pH adjusting chemicals, dyes and colorants, spices, surface active agents, thickeners, texturizers, salts, flavors, are examples of such additives.

20

For use in liquid foodstuffs or pharmaceuticals, the fermentation broth, optionally treated with a preservative, can directly be added into liquid medium. It is a simple mathematical calculation to determine how much of the broth should be added to the foodstuff or pharmaceutical. Simple analytical techniques can be used to determine the amount of the polysaccharide polymer in the broth. Using weight and volume analysis as would be well understood in the art would enable the practitioner to determine the equivalent volume of broth corresponding to a solid additive amount. For example, a formulation requiring 0.5 percent by weight of xanthan gum (solid) would require the addition of 12.5 parts of a xanthan broth having a concentration of 4% xanthan gum.

25

The fermentation broth can be used with any liquid foodstuff or pharmaceutical which would benefit from having the fermentation polymer in its formulation. In most applications, this would involve the use of the polymer as a viscosity agent, such as the use of xanthan gum as a thickening agent. Examples of the types of foods or pharmaceuticals in which the broth could be utilized include, but are not limited to the following classes of materials: salad dressings, sauces, soups, syrups, condiments, gravies, bakery fillings, puddings, gelatin desserts, beverages, milkshakes, frozen foods and pharmaceutical suspensions. In practice, the amount of broth added to such foods or pharmaceuticals is an amount so that the amount of active biopolymer ranges between about 0.01 to about 2.0 percent by weight of the final product, more preferably between about 0.1 to about 1.0 percent by weight of the final product.

It has been surprisingly discovered that the use of the inventive polymer broth can provide better viscosity performance in homogenized foods such as salad dressings. As will be demonstrated in the examples, when conducting direct comparisons between homogenized liquid foods, the use of a xanthan fermentation broth provides better viscosity performance as compared to the conventional addition of xanthan gum, namely addition in a powdered, purified form. In addition, because the biopolymer is already present in an aqueous environment, improved dispersibility results from using the broth directly into final formulated foods or pharmaceuticals.

The invention is described in greater detail by the following non-limiting examples.

Example 1 - Production of Fermentation Broth

For this synthesis the generally understood method for producing a xanthan gum fermentation broth is utilized (such as the methods as illustrated in prior art such as U.S. Patent Nos. 3,000,790; 3,020,207; 3,557,016 or 4,299,825). More specifically, a xanthan gum fermentation broth is prepared under biosynthesis conditions by fermentation of the microorganism *Xanthomonas campestris* operating on a substrate of hydrolyzed potato starch or equivalent sugar. After fermentation, the broth is heated and glacial acetic acid in an amount of about 10

percent by weight of the resulting broth is added to the broth in an amount so that the pH of the broth is lowered to 3.0. The percentage of xanthan gum present in the broth is 3.24% by weight of the broth.

5 Comparative Example 2 - Production of Xanthan Gum Powder

The typical post-fermentation processing steps are performed on the fermentation broth of Example 1 prior to the final heating and addition of glacial acetic acid. More specifically, the xanthan gum broth is heated, treated with isopropanol, precipitated, centrifuged, dried and milled
10 and sieved to yield a powder. The moisture content of the powder is 9.8%.

Example 3 - Hydration Properties of Example 1 and Comparative Example 2 Compositions

Two aqueous solutions are prepared for purposes of measuring hydration properties of the
15 Example 1 and Comparative Example 2 compositions. The amounts are added so that each aqueous solution contains 0.5% by weight of xanthan gum. The solutions are as follows. All parts are listed by weight.

Solution A

Component	Amount (by weight)
Example 1 Composition	17.089
Tripotassium Phosphate (1M)	15.190
Sodium Hydroxide (10N)	1.510
Distilled Water	66.211
TOTAL	100.00

Solution B

Component	Amount (by weight)
Comp. Ex. 2 Composition	0.5500
Tripotassium Phosphate (1M)	15.190
Sodium Hydroxide (10N)	1.5100
Distilled Water	81.0411
Glacial Acetic Acid	1.7089
TOTAL	100.00

5 To determine the hydration properties of the respective solutions, the following test procedures are utilized.

Waring Blender Method:

10 Solution A: In a mixer bowl, weigh an aqueous solution containing the tripotassium phosphate and sodium hydroxide and add preweighed liquid xanthan broth and turn on the mixer and increase the speed to 2000 rpm and mix for five minutes at 2000 rpm. After five minutes of mixing, the bowl is removed and the solution is poured into a 600 ml beaker. Using a Brookfield LV Viscometer, Spindle #3 or 4, 60 rpm a viscosity reading is taken. Measurements are taken every fifteen minutes thereafter until 60 minutes after initial agitation.

15

20 Solution B: In a mixer bowl weigh the water, turn on the mixer and increase speed to 2000 rpm. Sprinkle the gum into the vortex of the mixer and add over a one minute period. After five minutes of mixing, the glacial acetic acid, sodium hydroxide and tripotassium phosphate are added and mixing continues until the mixture is uniform in consistency. The bowl is removed and the solution is poured into a 600 ml beaker. Using a Brookfield LV Viscometer, Spindle #3 or 4, 60 rpm a

viscosity reading is taken. Measurements are taken every fifteen minutes thereafter until 60 minutes after initial agitation.

The viscosity profile for each of the Solutions is as follows. Measurements are in cps.:

Time	Solution A	Solution B
Initial	770	730
15 minutes	810	770
30 minutes	800	830
60 minutes	800	800

The above data demonstrates that the respective materials behave nearly identical in their hydration in water.

Example 4 - Salad Dressing Composition using Example 1 Composition

To produce a low fat (8% fat) Italian-type salad dressing using the liquid xanthan broth of Example 1, the following procedure is used. 6.00 parts of sucrose are added to 55.90 parts of water and the solution is mixed at 500 rpm for two minutes. 27.40 parts of the Example 1 Composition are slurried in 8.20 parts of soybean oil and this slurry is added to the water/sucrose solution and is mixed at 2000 rpm for 3 minutes. 2.50 parts of sodium chloride are added to the solution and the mixture is mixed at 2000 rpm for 3 minutes.

The mixture is split into two parts for comparative testing purposes. The first part is set aside for viscosity measurements and is referred to as Example 4A. The other part is continuously homogenized at 2500 pounds per square inch using a Microfluidics Homogenizer (HC-5000) and is then cooled to 25°C and is referred to as Example 4B. Viscosity measurements are taken on this part. Homogenization is performed in order to break down the fat present in the mixture to form a stable suspension.

All measurements are taken using a Brookfield LVT Viscometer using Spindle #3 or 4, at either 12 or 60 rpm. Measurements are taken at intervals of one, two, three days, one week, two weeks, three weeks and four week intervals. The results are shown in Figures 1 and 2.

5

Example 5 - Salad Dressing Composition using Comparative Example 2 Composition

To produce a low fat (8% fat) Italian-type salad dressing using the xanthan powder of Comparative Example 2, the following procedure is used. 6.00 parts of sucrose are added to
10 64.57 parts of water and the solution is mixed at 500 rpm for two minutes. 0.89 parts of the Comparative Example 2 Composition are slurried in 8.20 parts of soybean oil and this slurry is added to the water/sucrose solution and is mixed at 2000 rpm for 3 minutes. 2.50 parts of sodium chloride, 17.20 parts of vinegar (120 grain) and 0.64 parts of glacial acetic acid are added to the solution and the mixture is mixed at 2000 rpm for 3 minutes. The acetic acid and vinegar are
15 added to compensate for the acetic acid already present in the Example 1 Composition so that a like comparison can be made.

The mixture is split into two parts for comparative testing purposes. The first part is set aside for viscosity measurements and is referred to as Example 5A. The other part is continually
20 homogenized at 2500 pounds per square inch using a Microfluidics Homogenizer (HC-5000) and is then cooled to 25°C and is referred to as Example 5B. Viscosity measurements are taken on this part. Homogenization is performed in order to break down the fat present in the mixture to form a stable suspension.

25 All measurements are taken using a Brookfield LVT Viscometer at Spindle #3 or 4, at either 12 or 60 rpm. Measurements are taken at intervals of one, two, three days, one week, two weeks, three weeks and four weeks. The results are shown in Figures 1 and 2.

- As is seen in Figures 1 and 2, the compositions made from the liquid xanthan gum demonstrate superior hydration performance as compared to those made from powdered xanthan gum. In fact, for the homogenized samples, the hydration performance of the composition containing liquid xanthan gum (4B) is unexpectedly superior to that of the composition containing powder xanthan (5B). As is seen in the Figures, Example 4B initially shows a dramatic increase in viscosity after one day as compared to Example 5B, which loses a significant amount of viscosity. The viscosity of Example 4B actually shows an increase over the time period of two weeks to four weeks, whereas the viscosity of Example 5B either stays approximately the same or decreases.
- Accordingly, in addition to the tremendous processing cost savings associated with using a liquid fermentation broth directly into liquid foodstuffs or pharmaceuticals, the above data demonstrates unexpectedly good results when using the liquid fermentation product into processed foods, and particularly homogenized foods. In addition, because the biopolymer is already present in an aqueous environment, it has improved dispersibility features as compared to solid powders used as rheology/thickening agents.

Having described the invention in detail and by reference to the preferred embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the appended claims.

WHAT IS CLAIMED IS:

- 5 1. A food or pharmaceutical composition including a liquid fermentation composition comprising the fermentation product of a biologically active substance in a carbohydrate medium other than dairy whey wherein said fermentation composition has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition.
- 10 2. The food or pharmaceutical composition according to claim 1 wherein said fermentation product comprises xanthan gum.
- 15 3. The food or pharmaceutical composition according to claim 1 wherein said fermentation product is derived from bacteria belonging to the genus of either *Leuconostoc*, *Lactobacillus*, *Streptococcus*, *Alcaligenes*, *Saccharomyces*, *Pullularia*, or *Pseudomonas*.
4. The food or pharmaceutical composition according to claim 1 wherein said carbohydrate medium is selected from the group consisting of include glucose, dextrose, sucrose, fructose, mannose, lactose, oligosaccharides, starches, maltodextrins and mixtures thereof.
- 20 5. The food or pharmaceutical composition according to claim 4 wherein said carbohydrate medium comprises glucose or hydrolyzed starch.
6. The food or pharmaceutical composition according to claim 1 wherein said liquid fermentation composition further comprises one or more preservatives.
- 25 7. The food or pharmaceutical composition according to claim 6 wherein said preservative comprises acetic acid.
8. The food or pharmaceutical composition according to claim 1 wherein the liquid fermentation

composition is present in said food or pharmaceutical composition in an amount such that the amount of fermentation product ranges between about 0.01 to about 2.0 percent by weight of the composition.

- 5 9. The food or pharmaceutical composition according to claim 8 wherein the liquid fermentation composition is present in said food or pharmaceutical composition in an amount such that the amount of fermentation product ranges between about 0.1 to about 1.0 percent by weight of the composition.
- 10 10. The food or pharmaceutical composition according to claim 1 wherein said liquid fermentation composition further includes one or more additives selected from the group consisting of bactericides, pH adjusting chemicals, dyes and colorants, spices, surface active agents, thickeners, texturizers, salts and flavors.
- 15 11. The food or pharmaceutical composition according to claim 1 which is selected from the group consisting of salad dressings, sauces, soups, syrups, condiments, gravies, beverages, bakery fillings, puddings, gelatin desserts, milkshakes, frozen foods and pharmaceutical suspensions.
- 20 12. The food or pharmaceutical composition according to claim 11 which is homogenized.
- 25 13. A homogenized liquid food or pharmaceutical composition including a liquid thickening agent comprising the fermentation product of *Xanthomonas* bacteria in a carbohydrate medium other than dairy whey wherein said liquid thickening agent has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition
14. The homogenized liquid food or pharmaceutical composition according to claim 13 wherein said composition is either a sauce, condiment or salad dressing.

15. A method for making a food or pharmaceutical composition comprising the steps of:

(a) fermenting a biologically active substance in a carbohydrate medium other than dairy whey to yield a liquid fermentation product; and

5

(b) directly adding said liquid fermentation product to food or pharmaceutical ingredients to yield a food or pharmaceutical composition.

16. The method according to claim 15 wherein said fermentation product comprises xanthan gum.

10

17. The method according to claim 15 comprising the additional step of homogenizing said food or pharmaceutical composition after addition of the liquid fermentation product.

18. The method according to claim 15 wherein said carbohydrate medium is selected from the group consisting of include glucose, dextrose, sucrose, fructose, mannose, lactose, oligosaccharides, starches, maltodextrins and mixtures thereof.

15

19. The method according to claim 18 wherein said carbohydrate medium comprises glucose or hydrolyzed starch.

20


20. The method according to claim 15 wherein said liquid fermentation product further comprises one or more preservatives.

21. The method according to claim 20 wherein said preservative comprises acetic acid.

25


1/2

FIG. 1



2/2

FIG. 2



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/23904

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A23L1/054 A23L1/00 C12P19/06 A23L2/00 A23G3/00
 A23L1/39 A23L1/22 A23L1/24 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A23L C12P C08B A23G A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 070 722 A (STAUFFER CHEMICAL COMPANY) 26 January 1983 & US 442 128 A cited in the application -----	1, 13, 15
A	US 4 299 825 A (HO-LUN LEE) 10 November 1981 cited in the application -----	1
A	EP 0 609 995 A (CERESTAR HOLDING BV) 10 August 1994 -----	1, 13, 15

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 February 1999

Date of mailing of the international search report

22/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Caturla Vicente, V

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/23904

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 70722	A	26-01-1983	US 4442128 A	10-04-1984
			AT 12256 T	15-04-1985
			AU 550531 B	27-03-1986
			AU 8615182 A	27-01-1983
			CA 1181283 A	22-01-1985
			DK 296482 A,B,	21-01-1983
			IE 53608 B	21-12-1988
<hr/>				
US 4299825	A	10-11-1981	NONE	
<hr/>				
EP 609995	A	10-08-1994	AT 154394 T	15-06-1997
			DE 69403688 D	17-07-1997
			DE 69403688 T	25-09-1997
			DK 609995 T	27-10-1997
			ES 2102769 T	01-08-1997
			FI 940429 A	31-07-1994
			GR 3023763 T	30-09-1997
			JP 6319576 A	22-11-1994
			NO 940304 A	01-08-1994
			US 5480785 A	02-01-1996
<hr/>				